In 2008, the NIDDK initiated the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study which is prospectively enrolling adults and children with and without acute kidney injury (AKI) at Participating Clinical Centers (PCC). The goals of the study are to define the natural history of AKI;to evaluate the impact of the presence and severity of AKI on renal, cardiovascular and other clinical and patient-centered outcomes;and to identify predictors of adverse events after an episode of AKI. The ASSESS- AKI PCCs represent a broad spectrum of clinical settings ranging from cardiothoracic surgery to intensive care units to general hospital floors in a geographically diverse research consortium. The proposed ASSESS-AKI- Phase 2 will extend follow-up through September 30, 2018. It will offer a unique opportunity to leverage the existing effort and success of ASSESS-AKI-Phase 1 through long-term prospective follow-up of a matched cohort of participants with and without initial AKI for a variety of clinical outcomes that will support addressing novel scientific goals. The enclosed application is in response to RFA-DK-12-509, "Limited Competition for the Continuation of the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study (U01)," on behalf of the Kaiser Permanente Northern California/University of California, San Francisco PCC. The six Specific Aims to be addressed by the participating PCC sites and Data Coordinating Center are:
Aim 1) To re-enroll a high percentage of ASSESS-AKI participants into Phase 2;
Aim 2) To maintain outstanding levels of retention, data quality and outcome ascertainment among ASSESS-AKI participants;
Aim 3) To evaluate the association between AKI and markers of cardiac ischemia, fibrosis, and endothelial dysfunction as potential contributors to excess cardiovascular risk in patients with AKI;
Aim 4) To examine the impact of AKI on the future development of metabolic disturbances among ASSESS-AKI participants;
Aim 5) To employ unbiased proteomic techniques to identify novel urinary protein biomarkers at 3 months after an episode of transient AKI that identify patients at risk for progressive renal dysfunction;
and Aim 6) To promote and support the conduct of ancillary studies in ASSESS-AKI, including collaboration with the broader nephrology research community. Through the ongoing participation of the PCCs, ASSESS-AKI-Phase 2 will become an unparalleled resource that will expand the science related to AKI natural history as well as the impact of AKI on the development and progression of CKD, cardiovascular disease, survival, quality of life, functional status and other important outcomes.

Public Health Relevance

This project is the continuation of the NIDDK-sponsored Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study. ASSESS-AKI is a prospective cohort study that will enroll approximately 1500 adults and 100 children with and without acute kidney injury (AKI) at Participating Clinical Centers. The overarching goals of this renewal are to re-enroll a high percentage of ASSESS-AKI participants into Phase 2 while maintaining outstanding levels of retention, data quality and outcome ascertainment among ASSESS-AKI participants to complete the goals of Phase 1. We will also evaluate novel associations between AKI and markers of cardiac ischemia, fibrosis, endothelial dysfunction and metabolic and nutritional disturbances among ASSESS-AKI participants and employ unbiased proteomic techniques to identify novel urinary protein biomarkers at 3 months after an episode of transient AKI that identify patients at risk for progressive renal dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK082223-07S1
Application #
8890306
Study Section
Special Emphasis Panel (ZDK1-GRB-C (M1))
Program Officer
Kimmel, Paul
Project Start
2008-09-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$100,000
Indirect Cost
$33,747
Name
Kaiser Foundation Research Institute
Department
Type
DUNS #
150829349
City
Oakland
State
CA
Country
United States
Zip Code
94612
Parikh, Chirag R; Butrymowicz, Isabel; Yu, Angela et al. (2014) Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis 63:567-72
Hsu, Chi-Yuan; Liu, Kathleen D (2014) Cardiovascular events after AKI: a new dimension. J Am Soc Nephrol 25:425-7
Hsu, Chi-yuan (2012) Yes, AKI truly leads to CKD. J Am Soc Nephrol 23:967-9
Lee, Peter; Johansen, Kirsten; Hsu, Chi-yuan (2011) End-stage renal disease preceded by rapid declines in kidney function: a case series. BMC Nephrol 12:5
Coca, Steven G; Cho, Kerry C; Hsu, Chi-yuan (2011) Acute kidney injury in the elderly: predisposition to chronic kidney disease and vice versa. Nephron Clin Pract 119 Suppl 1:c19-24
Siew, Edward D; Matheny, Michael E; Ikizler, T Alp et al. (2010) Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int 77:536-42
Liu, Kathleen D; Chertow, Glenn M (2010) Curbing the use of ultrasonography in the diagnosis of acute kidney injury: Penny wise or pound foolish?: Comment on "Renal ultrasonography in the evaluation of acute kidney injury". Arch Intern Med 170:1907-8
Cho, Kerry; Hsu, Chi-yuan (2010) Quantifying severity of chronic kidney disease as a risk factor for acute kidney injury. J Am Soc Nephrol 21:1602-4
Go, Alan S; Parikh, Chirag R; Ikizler, T Alp et al. (2010) The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol 11:22
Hsu, Chi-yuan (2010) Where is the epidemic in kidney disease? J Am Soc Nephrol 21:1607-11

Showing the most recent 10 out of 14 publications